blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3661926

EP3661926 - SUBSTITUTED INDOLE COMPOUNDS USEFUL AS INHIBITORS OF TLR7/8/9 [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  30.12.2022
Database last updated on 27.07.2024
FormerThe patent has been granted
Status updated on  21.01.2022
FormerGrant of patent is intended
Status updated on  28.09.2021
FormerExamination is in progress
Status updated on  05.03.2021
FormerRequest for examination was made
Status updated on  08.05.2020
FormerThe international publication has been made
Status updated on  09.02.2019
Formerunknown
Status updated on  29.08.2018
Most recent event   Tooltip10.05.2024Lapse of the patent in a contracting state
New state(s): HU		published on 12.06.2024  [2024/24]
Applicant(s)For all designated states
Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton, NJ 08543 / US
[2020/24]
Inventor(s)01 / DYCKMAN, Alaric J.
c/o Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton New Jersey 08543 / US
02 / DODD, Dharmpal S.
c/o Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton New Jersey 08543 / US
03 / HAQUE, Tasir Shamsul
351 Denny Drive
Yardley Pennsylvania 19067 / US
04 / WHITELEY, Brian K.
1404 Us Hwy 22 West
Lebanon, NJ 08833 / US
05 / GILMORE, John L.
c/o Bristol-Myers Squibb Company
Route 206 and Province Line Road
Princeton New Jersey 08543 / US
 [2020/24]
Representative(s)Kling, Edouard
Swords Laboratories, Ireland
Swiss Branch, Steinhausen
Hinterbergstrasse 16
6312 Steinhausen / CH
[2020/24]
Application number, filing date18756116.203.08.2018
[2020/24]
WO2018US45082
Priority number, dateUS201762541335P04.08.2017         Original published format: US 201762541335 P
[2020/24]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2019028302
Date:07.02.2019
Language:EN
[2019/06]
Type: A1 Application with search report 
No.:EP3661926
Date:10.06.2020
Language:EN
The application published by WIPO in one of the EPO official languages on 07.02.2019 takes the place of the publication of the European patent application.
[2020/24]
Type: B1 Patent specification 
No.:EP3661926
Date:23.02.2022
Language:EN
[2022/08]
Search report(s)International search report - published on:EP07.02.2019
ClassificationIPC:C07D401/14, A61P29/00, A61P37/00, A61K31/444
[2020/24]
CPC:
C07D401/14 (EP,KR,US); A61K31/4545 (KR); A61P29/00 (EP,KR);
A61P37/00 (EP,KR); C07D405/14 (US); C07D409/14 (US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2020/24]
Extension statesBANot yet paid
MENot yet paid
Validation statesKHNot yet paid
MANot yet paid
MDNot yet paid
TNNot yet paid
TitleGerman:SUBSTITUIERTE INDOLVERBINDUNGEN ALS INHIBITOREN VON TLR7/8/9[2020/24]
English:SUBSTITUTED INDOLE COMPOUNDS USEFUL AS INHIBITORS OF TLR7/8/9[2020/24]
French:COMPOSÉS INDOLE SUBSTITUÉS UTILES EN TANT QU'INHIBITEURS DE TLR7/8/9[2020/24]
Entry into regional phase20.02.2020National basic fee paid 
20.02.2020Designation fee(s) paid 
20.02.2020Examination fee paid 
Examination procedure20.02.2020Examination requested  [2020/24]
20.02.2020Date on which the examining division has become responsible
27.08.2020Amendment by applicant (claims and/or description)
10.03.2021Despatch of a communication from the examining division (Time limit: M04)
24.06.2021Reply to a communication from the examining division
29.09.2021Communication of intention to grant the patent
13.01.2022Fee for grant paid
13.01.2022Fee for publishing/printing paid
13.01.2022Receipt of the translation of the claim(s)
Opposition(s)24.11.2022No opposition filed within time limit [2023/05]
Fees paidRenewal fee
13.08.2020Renewal fee patent year 03
13.08.2021Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU03.08.2018
AL23.02.2022
AT23.02.2022
CY23.02.2022
CZ23.02.2022
DK23.02.2022
EE23.02.2022
FI23.02.2022
HR23.02.2022
LT23.02.2022
LV23.02.2022
MC23.02.2022
MK23.02.2022
NL23.02.2022
PL23.02.2022
RO23.02.2022
RS23.02.2022
SE23.02.2022
SI23.02.2022
SK23.02.2022
SM23.02.2022
BG23.05.2022
NO23.05.2022
GR24.05.2022
IS23.06.2022
PT23.06.2022
IE03.08.2022
LU03.08.2022
BE31.08.2022
CH31.08.2022
LI31.08.2022
[2024/24]
Former [2024/23]AL23.02.2022
AT23.02.2022
CY23.02.2022
CZ23.02.2022
DK23.02.2022
EE23.02.2022
FI23.02.2022
HR23.02.2022
LT23.02.2022
LV23.02.2022
MC23.02.2022
MK23.02.2022
NL23.02.2022
PL23.02.2022
RO23.02.2022
RS23.02.2022
SE23.02.2022
SI23.02.2022
SK23.02.2022
SM23.02.2022
BG23.05.2022
NO23.05.2022
GR24.05.2022
IS23.06.2022
PT23.06.2022
IE03.08.2022
LU03.08.2022
BE31.08.2022
CH31.08.2022
LI31.08.2022
Former [2024/20]AL23.02.2022
AT23.02.2022
CY23.02.2022
CZ23.02.2022
DK23.02.2022
EE23.02.2022
FI23.02.2022
HR23.02.2022
LT23.02.2022
LV23.02.2022
MC23.02.2022
NL23.02.2022
PL23.02.2022
RO23.02.2022
RS23.02.2022
SE23.02.2022
SI23.02.2022
SK23.02.2022
SM23.02.2022
BG23.05.2022
NO23.05.2022
GR24.05.2022
IS23.06.2022
PT23.06.2022
IE03.08.2022
LU03.08.2022
BE31.08.2022
CH31.08.2022
LI31.08.2022
Former [2023/42]AL23.02.2022
AT23.02.2022
CZ23.02.2022
DK23.02.2022
EE23.02.2022
FI23.02.2022
HR23.02.2022
LT23.02.2022
LV23.02.2022
MC23.02.2022
NL23.02.2022
PL23.02.2022
RO23.02.2022
RS23.02.2022
SE23.02.2022
SI23.02.2022
SK23.02.2022
SM23.02.2022
BG23.05.2022
NO23.05.2022
GR24.05.2022
IS23.06.2022
PT23.06.2022
IE03.08.2022
LU03.08.2022
BE31.08.2022
CH31.08.2022
LI31.08.2022
Former [2023/33]AL23.02.2022
AT23.02.2022
CZ23.02.2022
DK23.02.2022
EE23.02.2022
FI23.02.2022
HR23.02.2022
LT23.02.2022
LV23.02.2022
MC23.02.2022
NL23.02.2022
PL23.02.2022
RO23.02.2022
RS23.02.2022
SE23.02.2022
SI23.02.2022
SK23.02.2022
SM23.02.2022
BG23.05.2022
NO23.05.2022
GR24.05.2022
IS23.06.2022
PT23.06.2022
IE03.08.2022
LU03.08.2022
CH31.08.2022
LI31.08.2022
Former [2023/21]AL23.02.2022
AT23.02.2022
CZ23.02.2022
DK23.02.2022
EE23.02.2022
FI23.02.2022
HR23.02.2022
LT23.02.2022
LV23.02.2022
MC23.02.2022
NL23.02.2022
PL23.02.2022
RO23.02.2022
RS23.02.2022
SE23.02.2022
SI23.02.2022
SK23.02.2022
SM23.02.2022
BG23.05.2022
NO23.05.2022
GR24.05.2022
IS23.06.2022
PT23.06.2022
LU03.08.2022
CH31.08.2022
LI31.08.2022
Former [2023/16]AL23.02.2022
AT23.02.2022
CZ23.02.2022
DK23.02.2022
EE23.02.2022
FI23.02.2022
HR23.02.2022
LT23.02.2022
LV23.02.2022
MC23.02.2022
NL23.02.2022
PL23.02.2022
RO23.02.2022
RS23.02.2022
SE23.02.2022
SI23.02.2022
SK23.02.2022
SM23.02.2022
BG23.05.2022
NO23.05.2022
GR24.05.2022
IS23.06.2022
PT23.06.2022
Former [2023/10]AL23.02.2022
AT23.02.2022
CZ23.02.2022
DK23.02.2022
EE23.02.2022
FI23.02.2022
HR23.02.2022
LT23.02.2022
LV23.02.2022
NL23.02.2022
PL23.02.2022
RO23.02.2022
RS23.02.2022
SE23.02.2022
SI23.02.2022
SK23.02.2022
SM23.02.2022
BG23.05.2022
NO23.05.2022
GR24.05.2022
IS23.06.2022
PT23.06.2022
Former [2023/01]AL23.02.2022
AT23.02.2022
CZ23.02.2022
DK23.02.2022
EE23.02.2022
FI23.02.2022
HR23.02.2022
LT23.02.2022
LV23.02.2022
NL23.02.2022
PL23.02.2022
RO23.02.2022
RS23.02.2022
SE23.02.2022
SK23.02.2022
SM23.02.2022
BG23.05.2022
NO23.05.2022
GR24.05.2022
IS23.06.2022
PT23.06.2022
Former [2022/49]AT23.02.2022
CZ23.02.2022
DK23.02.2022
EE23.02.2022
FI23.02.2022
HR23.02.2022
LT23.02.2022
LV23.02.2022
NL23.02.2022
PL23.02.2022
RO23.02.2022
RS23.02.2022
SE23.02.2022
SK23.02.2022
SM23.02.2022
BG23.05.2022
NO23.05.2022
GR24.05.2022
IS23.06.2022
PT23.06.2022
Former [2022/48]AT23.02.2022
CZ23.02.2022
DK23.02.2022
EE23.02.2022
FI23.02.2022
HR23.02.2022
LT23.02.2022
LV23.02.2022
NL23.02.2022
PL23.02.2022
RO23.02.2022
RS23.02.2022
SE23.02.2022
SM23.02.2022
BG23.05.2022
NO23.05.2022
GR24.05.2022
IS23.06.2022
PT23.06.2022
Former [2022/47]AT23.02.2022
DK23.02.2022
FI23.02.2022
HR23.02.2022
LT23.02.2022
LV23.02.2022
NL23.02.2022
PL23.02.2022
RO23.02.2022
RS23.02.2022
SE23.02.2022
SM23.02.2022
BG23.05.2022
NO23.05.2022
GR24.05.2022
IS23.06.2022
PT23.06.2022
Former [2022/46]AT23.02.2022
DK23.02.2022
FI23.02.2022
HR23.02.2022
LT23.02.2022
LV23.02.2022
NL23.02.2022
PL23.02.2022
RS23.02.2022
SE23.02.2022
BG23.05.2022
NO23.05.2022
GR24.05.2022
IS23.06.2022
PT23.06.2022
Former [2022/42]AT23.02.2022
FI23.02.2022
HR23.02.2022
LT23.02.2022
LV23.02.2022
NL23.02.2022
PL23.02.2022
RS23.02.2022
SE23.02.2022
BG23.05.2022
NO23.05.2022
GR24.05.2022
IS23.06.2022
PT23.06.2022
Former [2022/39]AT23.02.2022
FI23.02.2022
HR23.02.2022
LT23.02.2022
LV23.02.2022
NL23.02.2022
PL23.02.2022
RS23.02.2022
SE23.02.2022
BG23.05.2022
NO23.05.2022
GR24.05.2022
PT23.06.2022
Former [2022/36]AT23.02.2022
HR23.02.2022
LT23.02.2022
LV23.02.2022
NL23.02.2022
PL23.02.2022
RS23.02.2022
SE23.02.2022
BG23.05.2022
NO23.05.2022
GR24.05.2022
PT23.06.2022
Former [2022/35]HR23.02.2022
LT23.02.2022
NL23.02.2022
RS23.02.2022
SE23.02.2022
BG23.05.2022
NO23.05.2022
PT23.06.2022
Former [2022/34]LT23.02.2022
NL23.02.2022
NO23.05.2022
PT23.06.2022
Former [2022/33]LT23.02.2022
NO23.05.2022
Cited inInternational search[I]US2006235037  (PURANDARE ASHOK V [US], et al) [I] 1-11 * claim 1; examples; examples 81, 82, 98-145; paragraph [0002]; *;
 [IP]WO2018049089  (BRISTOL MYERS SQUIBB CO [US]) [IP] 1-11* examples;; claim 1 *
by applicant   - KAWAI, T. et al., Nature Immunol., (20100000), vol. 11, pages 373 - 384
    - SIMS, J.E. et al., Nature Rev. Immunol., (20100000), vol. 10, pages 89 - 102
    - A Textbook of Drug Design and Development, Harwood Academic Publishers, (19910000), pages 113 - 191
    - CHEMICAL ABSTRACTS, Database accession no. 87486-33-7
    - CHEMICAL ABSTRACTS, Database accession no. 137628-16-1
    - CHEMICAL ABSTRACTS, Database accession no. 1199773-45-9
    - CHEMICAL ABSTRACTS, Database accession no. 120034-05-1
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.